The EPS projection of Aduro BioTech Inc (NASDAQ:ADRO) for quarter ended 2016-09-30 is $-0.47. Last week, the EPS forecast was $-0.47 against target of $-0.47, a month earlier. Two months ago, this estimate was $-0.47 versus forecast of $-0.47 three months earlier, implying a deviation of 0%.
Aduro BioTech Inc (NASDAQ:ADRO) stated that 18 days ago, its stock price was positively revised 1 times while negative revisions were 1.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 1, 2, and 2, correspondingly.
EPS estimate downgrade for Aduro BioTech Inc (NASDAQ:ADRO) in the preceding 30, 120, 60 and 90 days were 0, 1, 2, and 2, correspondingly.
Aduro BioTech Inc (NASDAQ:ADRO) EPS target for the quarter closed 1 was $-0.47, based on 4 recommendations. As reported on 2016-05-02 the EPS was $-0.45. The change was $-0.15, implying a percentage deviation of -50%. The projections showed a standard deviation of 0.18.
Quarterly Sales Estimates
Aduro BioTech Inc (NASDAQ:ADRO) yearly sales prediction for the fiscal 2016 stands at $4.478 and the median estimate is at $3.902. Almost 4 analysts issued sales target.
Highest sales target is $6.41 while the lowest target is $3.7 showing standard deviation of 1.301%.
As many as 4 analysts have sales targets revised upside while 4 reduced sales estimates, implying a deviation of 0%.
Last month, 4 revised sales number projection on upside while 4 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast. Aduro BioTech Inc (NASDAQ:ADRO) announced that the deviation in forecast was -43.143%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...